Navigation Links
CONRAD presents new technology combining contraception, HIV and herpes simplex virus-2 prevention
Date:11/12/2013

Arlington, Va. CONRAD Head of drug delivery, Meredith Clark, PhD, today presented preclinical data on a new intravaginal ring that provides contraception as well as HIV-1 and HSV-2 prevention at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas. This multipurpose prevention technology (MPT) can remain in the vagina for up to 90 days and releases the contraceptive levonorgestrel (LNG) and tenofovir (TFV), an antiretroviral that inhibits HIV and HSV replication in susceptible cells.

The CONRAD product development team, in collaboration with Dr. Patrick Kiser at Northwestern University, performed in vitro release testing and 3-month pharmacokinetic (PK) studies of the ring in rabbits and sheep, and compared drug levels to those seen with use of tenofovir gel. The PK studies found that levels of tenofovir in the target tissue delivered from the ring are similar or higher than those obtained after TFV 1% gel application, a product that has proven to be effective in preventing HIV and HSV infections in women. In addition, release of the contraceptive agent was also consistent with previous levels tested to be efficacious in women. Stability studies will continue and lead to Phase I clinical trials in women in 2014, which will test the combination ring, as well as a tenofovir-only ring.

Tenofovir is the first microbicide proven to be efficacious in humans, with the CAPRISA 004 clinical trial showing that women using the gel before and after sex reduced their risk of HIV infection by 39-54%. CAPRISA 004 also showed the gel to be 51% effective in reducing the transmission of HSV-2, making this combination ring potentially triple protective.

"The TFV/LNG ring is the first device to be tested in women that will offer contraception as well as HIV and herpes prevention," said Dr. Clark. "And so far, tenofovir is the only microbicide that has been proven to be effective in redu
'/>"/>

Contact: Annette Larkin
alarkin@conrad.org
703-772-6427
CONRAD
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
4. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
5. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
6. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
7. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
8. Fusion presents low proliferation risk, experts conclude
9. ODT Forum Presents Regenerative Technologies
10. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
11. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CONRAD presents new technology combining contraception, HIV and herpes simplex virus-2 prevention
(Date:7/24/2014)... of Engineering at the University of Delaware, is ... in energy engineering, environmental sustainability and electronics. , ... rock with a well-defined, crystalline structure. At the ... decided that zeolites can separate molecules with size ... (one-tenth of a nanometer), making them useful to ...
(Date:7/24/2014)... Livermore, California (PRWEB) July 24, 2014 ... due to advances in modeling lithium-ion battery storage ... could benefit from a theoretical model created at ... Rice University that predicts how carbon components ... for energy storage emphasizes the urgent need for ...
(Date:7/24/2014)... 2014 Deep Research Report on ... professional and in-depth research report on Potassium Sulphate ... basic information, including its definition, classification, application, and ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis, the influence ...
(Date:7/24/2014)... 2014 The first part of the ... First in Human Studies” will cover comprehensive clinical support ... , With increasing R&D costs and declining industry success ... maximize the knowledge collected in early Phase I/IIa study ... in late stage development. , Next, the presenters will ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 33Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference 2Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference 3VIVUS to Present at Two Upcoming Investor Conferences 2
(Date:7/25/2014)... the colonial era, 100,000s of people lived on the ... manipulated fire to control the availability of plants they ... continue to use fire to maintain desired habitat and ... U.S. Forest Service,s Pacific Southwest Station, will lead a ... Wildfire Refuge during the Ecological Society of America,s 99th ...
(Date:7/25/2014)... SEATTLE, WA Nearly 600 scientists from 25 ... Yeast Genetics Meeting organized by the Genetics Society ... of Washington in Seattle. The conference will feature ... cutting-edge research results on topics including gene expression ... discovery, emerging technologies, evolution, aging, and a variety ...
(Date:7/25/2014)... bifda (SB) is a complex congenital central nervous ... closing of the neural tubes during the embryonic ... urinary and fecal incontinence and neurocognitive retardation. Such ... quality of life. Researchers at Ankara Physical Medicine ... the functional performance in children with SB, using ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... three-dimensional puzzles, Rubik,s Cube pales in comparison with the ... and collaborators Chuck DeMets of the University of Wisconsin-Madison ... Pasadena, Calif., have just put the finishing touches on ... the relative movements of the interlocking tectonic plates that ...
... when man and machine would become one. New research ... of bionics a reality. Prof. Yael Hanein of ... research that may give sight to blind eyes, merging ... so far in animal models, this research may one ...
... 20 project proposals across Africa to receive support from ... and to improve water-monitoring resources. TIGER II is ... TIGER I, which sought to help African countries overcome ... using Earth-observation (EO) technology. ,Under TIGER I, ...
Cached Biology News:Tectonics: Precision is hallmark of 20-year study 2Tectonics: Precision is hallmark of 20-year study 3Seeing a bionic eye on medicine's horizon 2ESA's TIGER II to support 20 water projects in Africa 2ESA's TIGER II to support 20 water projects in Africa 3
... II Microplate Handler is a high-capacity, ... integrating BioTeks washers, readers and liquid ... capacity, ultimate flexibility and intuitive and ... capacity to single devices or linking ...
... Kits enable rapid analytical to medium scale ... from appropriate vectors. Sufficient reagents are provided ... target protein under native or denaturing conditions. ... which specifically retains STag fusion proteins. After ...
... Biotech Solutions Group combines deep experience, skills ... qualities of collaborative team chemistry. This combination ... to approval and beyond.,With AAIBiotech, you can ... you get more than that: its the ...
S-100 alpha/beta chain (8B10)...
Biology Products: